Twelve-Month Outcomes of Standalone Travoprost Intracameral Implant in Glaucoma or Ocular Hypertension
Life · 07.04.2026 · 16 (4) · 614
DOI: 10.3390/life16040614 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life, online erschienen am 07.04.2026. Verfasst von Savak Teymoorian und 3 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Eye Associates, Laguna Hills, CA 92653, USA. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This retrospective study evaluated real-world outcomes of standalone iDose TR intracameral travoprost implant administration. Sixty-five consecutive standalone iDose TR implantations performed by a single surgeon were analyzed. Patients were pseudophakic, had a diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT), and had a history of a prior non-filtering glaucoma procedure (e.g., selective laser trabeculoplasty [SLT] or bimatoprost intracameral implant) performed beyond the preceding 6 months. Intraocular pressure (IOP) and medications were measured for 12 months postoperatively. Subgroup analysis was stratified by history of SLT treatment and glaucoma severity. If target IOP was not attained, secondary minimally invasive glaucoma surgery was performed instead of reinitiating or adding medication, according to the surgeon’s standard practice. The analysis was by intention to treat. At 12 months, mean IOP reduced significantly to 14.0 ± 2.9 mmHg from a baseline of 20.0 ± 4.0 mmHg (−28%, p < 0.001). Eyes with IOPs ≤ 18, ≤15, and ≤12 mmHg increased significantly vs. baseline (36.9% to 92.3%, 10.8% to 73.8%, and 3.1% to 35.4%, respectively; all p < 0.001), and 89.2% of the eyes were medication-free vs. 87.7% preoperatively. Mean 12-month IOP reduction showed nonsignificant differences between eyes with or without prior SLT (−26% and −31%, respectively; p = 0.907) and among mild/OHT, moderate, or severe glaucoma eyes (−28%, −23%, and −34%, respectively; p = 0.085). Postoperatively, one case each of transient corneal edema and retinal edema were observed, which self-resolved without sequelae. Thus, standalone travoprost implant administration significantly reduced IOP over 12 months in OAG and OHT, while maintaining a low medication burden. Similar IOP reductions were observed regardless of prior SLT treatment and glaucoma severity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Harvard Eye Associates, Laguna Hills, CA 92653, USA.
- Glaukos Corporation, Aliso Viejo, CA 92656, USA.
ORCID-Profile: Dana M Hornbeak
Zitieren
APA
Teymoorian, S., Kaur, J., Hornbeak, D. M., & Barr, E. (2026). Twelve-Month Outcomes of Standalone Travoprost Intracameral Implant in Glaucoma or Ocular Hypertension. Life, 16(4), 614. https://doi.org/10.3390/life16040614
Vancouver
Teymoorian S, Kaur J, Hornbeak DM, Barr E. Twelve-Month Outcomes of Standalone Travoprost Intracameral Implant in Glaucoma or Ocular Hypertension. Life. 2026;16(4):614. doi:10.3390/life16040614
BibTeX
@article{Teymoorian2026,
author = {Teymoorian, Savak and Kaur, Jasmin and Hornbeak, Dana M and Barr, Erik},
title = {Twelve-Month Outcomes of Standalone Travoprost Intracameral Implant in Glaucoma or Ocular Hypertension},
journal = {Life},
year = {2026},
volume = {16},
number = {4},
pages = {614},
doi = {10.3390/life16040614}
}
EUVIMED